We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are OK with this.     OK  No, I would like to know more...
Home / About Novasep / Media & Events / Press releases / Novasep launches AbSolute® High Cap - (10/31/2011)

Novasep launches AbSolute® High Cap - (10/31/2011)

31 Oct 2011

New protein A media boosts productivity in monoclonal and polyclonal antibody capture, lowers costs.

Pompey, France, October 31, 2011 – Novasep, a leading supplier of manufacturing solutions to the life sciences industries, announces today the launch of AbSolute® High Cap, a new generation Protein A media, based on modified silica.
 
Novasep’s AbSolute High Cap has been designed to offer the best performance for capturing both monoclonal and polyclonal antibodies from high titer and large volume feedstock. AbSolute High Cap’s productivity outperforms other approaches on the market by between 50 to 200 percent in a wide range of flow rates.

AbSolute High Cap will also enable biopharmaceutical companies to reduce significantly the cost of Protein A resins, with potential savings of up to a few million USD per year on a commercial scale.

The cost of downstream processing (DSP) is around 70 per cent of the manufacturing cost of mAb with the capture step being the single most costly step, as it uses the very expensive Protein A based affinity chromatography resins (media). Currently the market size of Protein A resins is estimated at USD 150 to 200 million.

Because of the high level of productivity achieved by using AbSolute High Cap, less resin is required to perform the purification of the same volume of fermentation feedstock. In this way, the new Novasep solution provides users with a step reduction in the cost of goods for monoclonal and polyclonal antibodies. Resin savings are estimated up to USD two million per year for large productions (for a 1.5 g/L mAb titer and 20,000 L bioreactors). This is particularly significant for the near term production of biosimilars because the cost of goods is more critical, but it should also be considered by any biotech that needs to scale up the production of their developmental antibodies and wants to significantly reduce their upfront consumables expense.

”The outstanding performance of AbSolute High Cap will enable its users to dramatically increase their production efficiency and decrease their costs of goods” said Antoine Baule, president of Novasep Process, the biomolecule division of Novasep. “We are delighted to launch this new product, which is another achievement of Novasep’s strategy to develop lean manufacturing solutions for our customers in the biopharmaceutical industry.”

AbSolute High Cap will be presented at the Bioprocess International Conference & Exhibition (October 31 - November 4 in Long Beach, California) in a technology workshop on "Rigid Porous Protein A Media - Progressing Towards a Revolution in mAb Capture" on Wednesday, November  2, 2011 at 12:00 p.m.


About Novasep
Novasep develops, markets and operates innovative technologies providing life science industries with safe and cost-effective production of active molecules.  The global manufacturing solutions offered by Novasep include process development services; purification equipment and systems; contract manufacturing services; and complex active molecules. The applications of Novasep's offering cover the pharmaceutical, biopharmaceutical, food, functional ingredients and bio-industries markets.

www.novasep.com

For further information, please contact:

Novasep
Jean Bléhaut
Director, Marketing & Business Development
 France : +33 383 49 7130

Andrew Lloyd & Associates
Neil Hunter
UK and US: +44 1273 675 100
Céline Gonzalez
France: +33 1 56 54 07 00

Novasep Icon PDF

 


Back to full list of events

You can stay on this page and select more documents or you can directly download the brochure(s) you selected
Give us your feedback!